First-in-Human Trial of BCMA-CD19 Compound CAR (cCAR) in Desensitization of Donor-Specific Anti-HLA Antibodies (DSAs) in Haploidentical Stem Cell Transplant Recipients
Latest Information Update: 19 Feb 2025
At a glance
- Drugs BCMA CD19 cCAR T-cell therapy-iCell Gene Therapeutics (Primary) ; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia; Paroxysmal nocturnal haemoglobinuria; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 19 Feb 2025 New trial record